News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
677,912 Results
Type
Article (38731)
Company Profile (248)
Press Release (638933)
Section
Business (203395)
Career Advice (1976)
Deals (35341)
Drug Delivery (78)
Drug Development (80558)
Employer Resources (167)
FDA (15988)
Job Trends (14776)
News (343470)
Policy (32401)
Tag
Academia (2528)
Africa (710)
Alliances (48938)
Alzheimer's disease (1134)
Approvals (15925)
Arizona (169)
Artificial intelligence (65)
Asia (36728)
Australia (5974)
Bankruptcy (350)
Best Places to Work (11229)
Biosimilars (62)
Biotechnology (172)
C2C Services and Suppliers (78801)
California (1648)
Canada (860)
Cancer (337)
Career advice (1646)
Cell therapy (101)
China (120)
Clinical research (62971)
Collaboration (112)
Colorado (65)
Compensation (61)
Connecticut (64)
COVID-19 (2479)
Cystic fibrosis (72)
Data (169)
Diabetes (70)
Diagnostics (5950)
Drug pricing (61)
Earnings (83621)
Employer resources (142)
Europe (78443)
Events (107525)
Executive appointments (111)
FDA (16171)
Florida (230)
Funding (108)
Gene therapy (80)
GLP-1 (500)
Government (4283)
Healthcare (18581)
Hotbed/Location (480970)
Illinois (239)
Indiana (136)
Infectious disease (2503)
Inflammatory bowel disease (86)
Interviews (305)
IPO (16173)
Job creations (3618)
Job search strategy (1411)
Kansas (93)
Layoffs (391)
Legal (7827)
Lung cancer (73)
Manufacturing (74)
Maryland (358)
Massachusetts (1358)
Medical device (13018)
Medtech (13021)
Mergers & acquisitions (18995)
Metabolic disorders (223)
Michigan (118)
Minnesota (205)
Neuroscience (1259)
New Jersey (499)
New York (518)
NextGen Class of 2024 (6478)
Non-profit (4452)
North Carolina (572)
Northern California (747)
Obesity (137)
Ohio (98)
Opinion (169)
Patents (63)
Pennsylvania (537)
People (55737)
Pharmaceutical (59)
Phase I (19504)
Phase II (27735)
Phase III (20729)
Pipeline (99)
Postmarket research (2546)
Preclinical (8297)
Press Release (64)
Rare diseases (116)
Real estate (5879)
Recruiting (63)
Regulatory (21150)
Research institute (2301)
Resumes & cover letters (345)
South America (1084)
Southern California (667)
Startups (3554)
Texas (200)
United States (7707)
Vaccines (451)
Washington State (236)
Weight loss (119)
Date
Today (6)
Last 7 days (578)
Last 30 days (2031)
Last 365 days (37163)
2024 (25013)
2023 (40074)
2022 (51174)
2021 (55713)
2020 (54087)
2019 (46541)
2018 (35020)
2017 (32111)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
677,912 Results for "rezolute inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Rezolute to Participate in the Jefferies Global Healthcare Conference
Rezolute, Inc. for serious metabolic and rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:00 p.m. ET in New York City.
May 30, 2024
·
1 min read
Business
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today reported financial results and provided a business update for the three months ended March 31, 2024.
May 15, 2024
·
8 min read
Pharm Country
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - June 13, 2024
Rezolute, Inc., a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, announced that it is commencing an underwritten public offering of shares of its common stock.
June 13, 2024
·
4 min read
Pharm Country
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Rezolute, Inc. announced that the underwriters of its previously announced public offering, which closed on June 24, 2024, have exercised an over-allotment option to purchase an additional 1,786,589 shares of the Company’s common stock at the public offering price of $4.00 per share, less underwriting discounts and commissions.
June 27, 2024
·
4 min read
Press Releases
Rezolute to Participate in Upcoming Investor Conferences
August 27, 2024
·
1 min read
Pharm Country
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
Rezolute, Inc. announced the closing of its underwritten public offering of 11,250,000 shares of its common stock at a price to the public of $4.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,750,000 shares of its common stock at a price to the public of $3.999 per pre-funded warrant, in each case, before underwriting discounts and commissions.
June 24, 2024
·
4 min read
Drug Development
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”) today announced positive topline results from the Phase 2 clinical study of RZ402 in patients with DME who are naïve to or have received limited anti-vascular growth factor (anti-VEGF) injections.
May 21, 2024
·
8 min read
Pharm Country
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
Rezolute, Inc. announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant.
June 13, 2024
·
4 min read
Press Releases
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 31, 2024
·
1 min read
Business
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the second quarter of fiscal 2024 ended December 31, 2023, and provided an update on recent business developments and outlook.
February 13, 2024
·
8 min read
1 of 67,792
Next